BioCryst's persistence for patient insights leads to a bigger market for HAE drug Orladeyo

Sometimes finding out how patients really feel about treatment takes persistence. That's what BioCryst Pharmaceuticals learned when it started talking to patients about its new oral preventative treatment for hereditary angioedema.